| Cash flow (USD) | FY 2025 ended Nov 30, 2025 | FY 2024 ended Nov 30, 2024 | FY 2023 ended Nov 30, 2023 | FY 2022 ended Nov 30, 2022 | FY 2021 ended Nov 30, 2021 | FY 2020 ended Nov 30, 2020 |
|---|---|---|---|---|---|---|
| Net income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M |
| Depreciation and amortization | 8.74M | 9.32M | 7.53M | 5.35M | 2.79M | 2.18M |
| Stock-based compensation | 37.97M | 33.93M | 33.67M | 28.13M | 15.80M | 4.30M |
| Cash from operations | -249.47M | -172.58M | -81.36M | -159.81M | -84.36M | -80.0K |
| Capital expenditure | -14.00M | -9.27M | -8.40M | -12.24M | -5.66M | -4.55M |
| Free cash flow | -263.47M | -181.86M | -89.77M | -172.05M | -90.03M | -4.63M |
| Cash from investing | 147.85M | -257.71M | 68.30M | 27.20M | -108.25M | -254.40M |
| Cash from financing | 238.64M | 485.67M | 3.22M | 117.19M | 153.88M | 339.02M |
| Net change in cash | 137.03M | 55.37M | -9.85M | -15.42M | -38.73M | 84.54M |
From Nurix Therapeutics, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.